Alzheimer’s disease is the leading cause of dementia affecting 13% of the population over the age of 65 years (US) with an economic impact estimated to be around a trillion US dollars per annum.

The cause and progression of the disease is not well understood, however, several hypotheses have been the target of drug discovery research in recent years. Arguably the most widely studied include the cholinergic, amyloid and tau hyperphosphorylation hypotheses.

Our research is involved in the development of novel duel inhibitors targeting Alzheimer’s disease by increasing the levels of acetyl choline in the brain and inhibiting the formation of Amyloid-beta aggregates, both hallmarks of the disease. Our research is aims to achieve this through the inhibition of acetylcholinesterase which regulates the breakdown and clearance of acetyl choline by targeting the enzymes catalytic triad and concurrently inhibiting amyloid-beta aggregation by targeting the enzymes peripheral anionic site.